ClinicalTrials.gg
RecruitingNCT06977594Updated Oct 7, 2026

Proactive Immune Tolerance Induction in Chemotherapy for Gynecologic Cancer

An interventional study of Proactive immune tolerance induction and Standard Treatment in Ovarian Cancer, Endometrial Cancer and Cervical Cancer, sponsored by Seoul National University Hospital. Recruiting at 1 site in South Korea. Open to female participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.
Updated Oct 7, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,000
Allocation
Randomized
Ages
19 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Ovarian Neoplasms by Seoul National University Hospital — 5 open to participants now, 6 under way, 1 of them phase 3. Ovarian Neoplasms · Seoul National University Hospital.

Started
2025
the only one that year
No phase
2 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Ovarian Neoplasms by Seoul National University Hospital, this one is the only one that started in 2025, is one of 2 with no phase, and was the 10th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

5 of the 11 studies in Ovarian Neoplasms by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 19 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Ovarian Neoplasms by Seoul National University Hospital, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the efficacy of proactive immune tolerance induction of chemotherapy (paclitaxel and carboplatin) for patients with gynecologic cancer.

The main questions it aims to answer are:

- Does immune tolerance induction during the first three cycles of chemotherapy reduce the incidence of hypersensitivity reactions in the remaining cycles?

Participants will:

  • Undergo immune tolerance induction or standard treatment during the first three cycles of chemotherapy as randomized, after which all participants will continue the remaining cycles with standard treatment.
  • Receive a reduced dose of dexamethasone premedication if assigned to the experimental group, depending on the specific protocol of each clinical trial.
Read the detailed description

Proactive immune tolerance induction is applied using an automated infusion pump with a pre-programmed protocol. It follows the same stepwise dosing scheme as conventional desensitization therapy used in patients who have experienced hypersensitivity reactions before. However, it is uniquely performed in patients without a prior history of hypersensitivity reactions, aiming to prevent sensitization itself.

03

Conditions studied

  • Ovarian Cancer
  • Endometrial Cancer
  • Cervical Cancer

Keywords

  • Immune tolerance induction
  • Desensitization
  • Drug hypersensitivity
  • Chemotherapy
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients receiving paclitaxel and carboplatin chemotherapy for gynecologic .
  • Patients with no prior history of reactions to paclitaxel or carboplatin.
  • Patients who are able to read and voluntarily provide written .
  • Aged 19 years or older.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not wish to participate in this study voluntarily.
  • Patients who, in the opinion of the investigator, are unsuitable for participation in this clinical trial.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,000 participants (estimated)

Study arms

  • Experimental
    (Trial 1) Proactive immune tolerance induction with 20 mg dexamethasone as premedication

    Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 20 mg of dexamethasone.

    Other: Proactive immune tolerance induction · Drug: Paclitaxel and carboplatin · Drug: Standard premedication (20 mg)

  • Active comparator
    (Trial 1) Standard treatment (placebo) with 20 mg dexamethasone as premedication

    Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.

    Other: Standard Treatment · Drug: Paclitaxel and carboplatin · Drug: Standard premedication (20 mg)

  • Experimental
    (Trial 2) Proactive immune tolerance induction with 10 mg dexamethasone as premedication

    Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 10 mg of dexamethasone.

    Other: Proactive immune tolerance induction · Drug: Paclitaxel and carboplatin · Drug: Reduced premedication (10 mg)

  • Active comparator
    (Trial 2) Standard treatment (placebo) with 20 mg dexamethasone as premedication

    Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.

    Other: Standard Treatment · Drug: Paclitaxel and carboplatin · Drug: Standard premedication (20 mg)

  • Experimental
    (Trial 3) Proactive immune tolerance induction with 5 mg dexamethasone as premedication

    Participants will receive proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles. Premedication includes 5 mg of dexamethasone.

    Other: Proactive immune tolerance induction · Drug: Paclitaxel and carboplatin · Drug: Reduced premedication (5 mg)

  • Active comparator
    (Trial 3) Standard treatment (placebo) with 20 mg dexamethasone as premedication

    Participants will receive standard treatment throughout all chemotherapy cycles. Premedication includes 20 mg of dexamethasone.

    Other: Standard Treatment · Drug: Paclitaxel and carboplatin · Drug: Standard premedication (20 mg)

Interventions

  • OtherProactive immune tolerance induction

    Proactive immune tolerance induction during the first three cycles of chemotherapy, followed by standard treatment in the remaining cycles

  • OtherStandard Treatment

    Standard treatment throughout all chemotherapy cycles

  • DrugPaclitaxel and carboplatin

    Drug pages: PaclitaxelStudies of PaclitaxelPaclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · CarboplatinStudies of CarboplatinCarboplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    A chemotherapy regimen for gynecologic cancers.

  • DrugStandard premedication (20 mg)

    Premedication includes 20 mg of dexamethasone.

  • DrugReduced premedication (10 mg)

    Premedication includes 20 mg of dexamethasone.

  • DrugReduced premedication (5 mg)

    Premedication includes 5 mg of dexamethasone.

06

What researchers measure

Primary outcomes

  1. Hypersensitivity reaction incidence

    Hypersensitivity reaction incidence (%) is calculated as (number of hypersensitivity reaction cases / total chemotherapy administrations) × 100. Hypersensitivity reaction will be defined as a Grade ≥2 event according to Common Terminology Criteria for Adverse Events (CTCAE), or a moderate or higher event according to Brown's criteria.

    Time frame: From the initiation of each chemotherapy cycle to 2 weeks after its administration in each patient (to identify not only immediate but also delayed hypersensitivity reactions).

Secondary outcomes

  1. Chemotherapy completion rate

    Chemotherapy completion rate is defined as the proportion of patients who completed all planned chemotherapy cycles as originally scheduled at treatment initiation.

    Time frame: From chemotherapy initiation to the last cycle in each patient, an average of 6 months

  2. Severity of hypersensitivity reaction

    Severity of hypersensitivity reactions will be classified according to the Common Terminology Criteria for Adverse Events (CTCAE).

    Time frame: From the initiation of each chemotherapy cycle to 2 weeks after its administration in each patient (to identify not only immediate but also delayed hypersensitivity reactions).

  3. Patients' quality of life

    Patients' quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Scores range from 0 to 100. Higher scores indicate better outcomes for the Global Health Status and Functional Scales, whereas higher scores on the Symptom Scales indicate worse symptoms.

    Time frame: From chemotherapy initiation to the last cycle, an average of 6 months

  4. Tumor Response Rate

    Tumor response rate is defined as the proportion of patients who experience tumor size reduction or disappearance in response to chemotherapy. It is calculated as the proportion of patients who achieve a complete response (disappearance of all tumors with no evidence of new lesions) or a partial response (at least a 30% reduction in the size of tumors, with no appearance of new lesion) after planned chemotherapy.

    Time frame: At every third chemotherapy cycle in each patient

  5. Survival rate

    Survival rate is defined as the proportion of patients who remain alive, with or without disease, after completion of the planned chemotherapy.

    Time frame: At study completion in each patient, an average of 1 year

  6. Recurrence Rate

    Recurrence rate is defined as the proportion of patients who experience a return of disease after achieving a response to treatment.

    Time frame: At study completion in each patient, an average of 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — IPD will not be shared due to institutional policies regarding data confidentiality.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 284 non-industry interventional studies with no phase under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 76. This study's planned 24 months is below that.

Counting every sponsor, half of 295 studies reached it within 46 months; a quarter within 23 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Jun 2025 → May 2025, on Oct 7, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 3, 2025
First posted
May 18, 2025
StartActual
May 21, 2025was Jun 2025
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 7, 2026
Sites
Seoul National University Hospital is now Recruiting
Oct 7, 2026
Start date
Jun 25, 2025→May 21, 2025 (actual)
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Not yet recruiting→Recruiting
    Seoul National University Hospital is now Recruiting
    Start date Jun 25, 2025→May 21, 2025 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06977594
Collaborators
Seoul National University Bundang Hospital, Seoul National University Boramae Hospital, Korea Health Industry Development Institute
Responsible party
Hye-Ryun Kang (Professor, Seoul National University Hospital) — Principal investigator
First posted
May 18, 2025
Start date
May 21, 2025
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Hye-Ryun Kang, MD, PhD
Contact
helenmed@snu.ac.kr
+82-2-2072-0820
Jiyeon Park, MD
Contact
creativepennant@snu.ac.kr
+82-2-2072-3291

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion